TuisPTCT • NASDAQ
add
PTC Therapeutics, Inc.
Vorige sluiting
$51,73
Dagwisseling
$51,56 - $52,98
Jaarwisseling
$28,72 - $58,38
Markkapitalisasie
4,13 mjd USD
Gemiddelde volume
1,41 m
P/V-verhouding
8,02
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,18 mjd | 459,73% |
Bedryfskoste | 84,76 m | -32,09% |
Netto inkomste | 866,56 m | 1 046,28% |
Netto winsgrens | 73,68 | 269,07% |
Wins per aandeel | 10,04 | 936,67% |
EBITDA | 976,72 m | 9 824,03% |
Effektiewe belastingkoers | 6,80% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,04 mjd | 128,74% |
Totale bates | 2,66 mjd | 48,38% |
Totale aanspreeklikheid | 2,84 mjd | 5,87% |
Totale ekwiteit | -185,76 m | — |
Uitstaande aandele | 79,26 m | — |
Prys om te bespreek | -22,11 | — |
Opbrengs op bates | 111,17% | — |
Opbrengs op kapitaal | 131,89% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 866,56 m | 1 046,28% |
Kontant van bedrywe | 870,10 m | 1 129,64% |
Kontant van beleggings | -184,36 m | -60,41% |
Kontant van finansiering | 9,41 m | 1 642,59% |
Netto kontantverandering | 700,55 m | 1 634,23% |
Beskikbare kontantvloei | 551,23 m | 1 102,29% |
Meer oor
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
Gestig
01 Jan. 1998
Hoofkwartier
Webwerf
Werknemers
939
